<DOC>
	<DOCNO>NCT02197637</DOCNO>
	<brief_summary>The purpose study determine whether oral vinorelbine effective treatment child progressive recurrent unresectable low grade glioma .</brief_summary>
	<brief_title>Phase II Trial Oral Vinorelbine Children With Recurrent Progressive Unresectable Low-Grade Glioma</brief_title>
	<detailed_description>The aim study determine efficacy oral vinorelbine child progressive recurrent unresectable low grade glioma , addition safety , pharmacokinetic , pharmacogenetic , medical cost quality life .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>TUMOR CHARACTERISTICS : Histologically confirm recurrent progressive primary LowGrade Glioma ( LGG ) define follow ( WHO classification 2007 ) : optic pathway glioma ( OPG ) , pilocytic astrocytoma ( PA ) , fibrillary diffuse astrocytoma ( DA ) , oligodendroglioma ( OG ) oligoastrocytoma ( OA ) Patients OPG require biopsy confirmation disease , clinical radiological finding well ophthalmological examination unequivocal LowGrade Glioma involve brainstem include case histological confirmation Tumor consider non totally resectable PATIENT CHARACTERISTICS : Age 618 year old Lansky Karnofsky status 50 % Measurable disease cerebral and/or spinal MRI , least 1 lesion diameter superior 1 cm Patients metastatic disease eligible , least 1 lesion must measurable previously define Patients must receive least 1 prior chemotherapy regimen contain carboplatin Life expectancy least 3 month Evidence adequate organ function , include : neutrophil count ( ANC ) ≥ 1500/mm3 , platelet count ≥100 000/mm3 ; serum creatinine &lt; 1.5 x normal age serum creatinine ≥ 1.5 × ULN , glomerular filtration rate ( either estimate formal ) must &gt; 70 mL/min/1.73m2 ; total bilirubin &lt; 1.5 x normal age , ASAT ALAT &lt; 2.5 x normal age Effective contraception patient ( male female ) reproductive potential , minimum 3 month end treatment Negative pregnancy test , applicable Patients able swallow capsule Patient affiliate health insurance system Written inform consent patient and/or parents/guardians prior study participation . PRIOR OR CONCURRENT THERAPY Prior treatment contain vinca alkaloid like vincristine and/or vinblastine authorize Patients must fully recover toxic effect prior therapy enter study . No organ toxicity superior grade 2 accord NCICTCAE v4.0 An interval least 2 month prior radiotherapy , 6 week nitrosourea chemotherapy , 4 week chemotherapy regimen , require Inclusion criterion failure Prior treatment intravenous oral vinorelbine Known hypersensibility vincaalkaloïdes Digestive pathology affect absorption important way Prior surgical resection stomach small intestine Severe hepatic failure independent tumoral disease Fructose intolerance Leptomeningeal relapse without available measurable disease MRI ( example , leptomeningeal relapse totally resect primary lesion ) Uncontrolled active infection within 2 week Pregnancy breast feed woman Uncontrolled intercurrent illness active infection Unsuitable medical followup ( geographic , social mental reason ) Patients require longterm oxygen therapy Patients ANC le 1500/mm3 Patients vaccinate yellow fever</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>